*Applications will be reviewed on a rolling-basis.
A research opportunity is currently available in the Division of Plasma Protein Therapeutics (DPPT), within the Office of Tissues and Advanced Therapies (OTAT), at the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA) in Silver Spring, Maryland.
The participant will join a research program that is involved in the design, development and validation of novel antibodies that target the spike protein of the SARS-CoV-2 virus with high affinity and neutralize infection. The participant will collaborate closely with computational and experimental biologists and immunologists to assay the binding affinities and neutralization efficacy of novel anti-SARS-CoV-2 antibodies, and will learn techniques for laboratory-based and computational assessment and evaluation of experimental plasma-derived therapeutics for COVID-19 disease.
Anticipated Appointment Start Date: September 1, 2021; start date is flexible
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.
If you have questions, send an email to ORISE.FDA.CBER@orau.org. Please include the reference code for this opportunity in your email.